Skip to content
DataLookout
Menu

NCT03970096

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 32 versions: 25 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 31, 2027 to Dec 31, 2028 Show 4 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Study completion pushed from Dec 31, 2029 to Dec 31, 2030
    • Secondary endpoints: details revised at 3 of 5 entries
    • Site details revised at 1 of 3 sites
  2. Notable Primary completion date: Dec 31, 2026 to Dec 31, 2027
    • Study completion date: Dec 31, 2028 to Dec 31, 2029
    v31
  3. Notable Eligibility criteria expanded, about 6 wordsv27
  4. Notable Eligibility criteria revisedv26
  5. Notable Eligibility criteria expanded, about 16 words
    • Interventions: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Busulfan (Drug), Cyclophosphamide (Drug), Cyclosporine (Drug)… to Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Biospecimen Collection (Procedure), Bone Marrow Aspiration and Biopsy…
    • Study description expanded, about 32 words
    v25
Show 19 earlier versionsHide 19 earlier versions
  1. Notable Primary completion date: Aug 1, 2025 to Dec 31, 2026
    • Study completion date: Aug 1, 2026 to Dec 31, 2028
    v24
  2. Minor Study description expanded, about 24 wordsv23
  3. Notable Eligibility criteria shortened, about 27 words
    • Site details revised at 1 of 3 sites
    v22
  4. Notable Eligibility criteria expanded, about 7 wordsv21
  5. Notable Primary completion date: Aug 1, 2023 to Aug 1, 2025
    • Study completion date: Aug 1, 2024 to Aug 1, 2026
    v20
  6. Minor Study description expanded, about 182 words
    • Study arms: 4 to 6
    v19
  7. Notable Eligibility criteria expanded, about 73 words
    • Study description shortened, about 184 words
    • Study arms: 6 to 4
    • Study title expanded, about 4 words
    v16
  8. Notable Eligibility criteria expanded, about 16 words
    • Interventions: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Cyclophosphamide (Drug), Cyclosporine (Drug), Fludarabine (Drug)… to Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Busulfan (Drug), Cyclophosphamide (Drug), Cyclosporine (Drug)…
    • Study description expanded, about 313 words
    • Study arms: 3 to 6
    v15
  9. Notable Eligibility criteria expanded, about 16 wordsv14 Show 5 more changesShow less
    • Enrollment target: 160 to 120
    • Interventions: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells… to Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Cyclophosphamide (Drug), Cyclosporine (Drug), Fludarabine (Drug)…
    • Secondary endpoints revised (5)
    • Study description shortened, about 52 words
    • Study arms: 4 to 3
  10. Notable Eligibility criteria expanded, about 19 wordsv13
  11. Minor Site details revised at 1 of 3 sitesv12
  12. Notable Eligibility criteria expanded, about 2 words
    • Study description revised
    v11
  13. Minor Interventions: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells… to Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells…
    • Secondary endpoints: details revised at 1 of 5 entries
    • Study description expanded, about 27 words
    v10
  14. Notable Eligibility criteria revised
    • Study sites: 2 to 3
    • Interventions: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells… to Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells…
    v8
  15. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Nov 15, 2019 to Nov 19, 2019
    • Site details revised at 2 of 2 sites
    v6
  16. Notable Start date: Oct 15, 2019 to Nov 15, 2019v5
  17. Minor Start date: Sep 19, 2019 to Oct 15, 2019v4
  18. Notable Start date: Aug 8, 2019 to Sep 19, 2019v3
  19. Notable Start date: Jul 6, 2019 to Aug 8, 2019v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Graft versus host disease (GVHD)-free relapse-free survival (RFS)
Timeframe: At 2 years

Secondary (5)

Overall survival (OS)
Relapse
Proportion of patients alive and off prednisone (or equivalent systemic corticosteroid) for treatment of GVHD
Graft rejection or irreversible graft failure (> 14 days duration)
Incidence of chronic GVHD

Arms and interventions

Arm A1 (TBI, TnD)Experimental

Patients undergo TBI BID on days -10 to -7, and receive thiotepa IV over 3 hours on days -6 and -5, fludarabine IV over 30 to 60 minutes on days -6 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.

Arm A2 (busulfan, TnD)Experimental

Patients receive fludarabine IV over 30 to 60 minutes on days -6 to -2, busulfan IV over 180 minutes on days -5 to -2, and undergo TBI BID on day -1. Patients also receive tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.

Arm C1 (TBI, PTCy, tacrolimus)Experimental

Patients undergo TBI BID on days -4 to -2 or -3 to -1, and receive PBSC IV on day 0. Patients also receive cyclophosphamide IV over 1 to 2 hours on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.

Arm C2 (busulfan, PTCy, tacrolimus)Experimental

Patients receive fludarabine IV over 30 to 60 minutes on days -5 to -2, busulfan IV over 180 minutes on days -5 to -2, PBSC IV on day 0, cyclophosphamide IV over 1 to 2 hours on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.

Arm D1 (TBI, tacrolimus, methotrexate) [DISCONTINUED NOVEMBER 2021]Experimental

Patients undergo TBI BID on days -6 to -4, and receive cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.

Arm D2 (busulfan, tacrolimus, methotrexate) [DISCONTINUED NOVEMBER 2021]Experimental

Patients receive busulfan IV over 180 minutes on days -8 to -5, cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.

Radiation: Total-Body Irradiation

Drugs: Thiotepa, Fludarabine, Tacrolimus, Methotrexate, Cyclophosphamide, Cyclosporine, Sirolimus, Busulfan

Biologicals: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Peripheral Blood Stem Cell

Procedures: Bone Marrow Aspiration and Biopsy, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection

Sites

3 sites in 1 country